Renaming non-alcoholic fatty liver disease:from metabolic dysfunction-associated fatty liver heterogeneity to"different treatment for the same disease"
The renaming of non-alcoholic fatty liver disease(NAFLD)to metabolic dysfunction-associated fatty/steatotic liver disease(MAFLD/MAFLD)has been controversial for the last two years,during which the re-sults of big data studies have proved the age-old limitations of NAFLD.Revisiting the nomenclature will allow for a proper understanding of the key causative factors of NAFLD,and an appreciation of its heterogeneity and differ-ent clinical phenotypes.The clinical response rate of NAFLD drug therapy is not high.By analyzing its heteroge-neity and combining it with the theory of"different treatment for the same disease"in traditional Chinese medi-cine,we can provide references for clinical diagnosis,research,and treatment of NAFLD.
万方数据
